Quantum computers promise scalable treatments of electronic structure, yet applying variational quantum eigensolvers (VQE) on realistic drug-like molecules remains constrained by the performance limitations of near-term quantum hardwares. A key strategy for addressing this challenge which effectively leverages current Noisy Intermediate-Scale Quantum (NISQ) hardwares yet remains under-benchmarked is active space selection. We introduce a benchmark that heuristically proposes criteria based on chemically grounded metrics to classify the suitability of a molecule for using quantum computing and then quantifies the impact of active space choices across the VQE pipeline for quantum drug discovery. The suite covers several representative drug-like molecules (e.g., lovastatin, oseltamivir, morphine) and uses chemically motivated active spaces. Our VQE evaluations employ both simulation and quantum processing unit (QPU) execution using unitary coupled-cluster with singles and doubles (UCCSD) and hardware-efficient ansatz (HEA). We adopt a more comprehensive evaluation, including chemistry metrics and architecture-centric metrics. For accuracy, we compare them with classical quantum chemistry methods. This work establishes the first systematic benchmark for active space driven VQE and lays the groundwork for future hardware-algorithm co-design studies in quantum drug discovery.
Comments
All kinds of discussions and suggestions are welcome
Quantum computers promise scalable treatments of electronic structure, yet applying variational quantum eigensolvers (VQE) on realistic drug-like molecules remains constrained by the performance limitations of near-term quantum hardwares. A key strategy for addressing this challenge which effectively leverages current Noisy Intermediate-Scale Quantum (NISQ) hardwares yet remains under-benchmarked is active space selection. We introduce a benchmark that heuristically proposes criteria based on chemically grounded metrics to classify the suitability of a molecule for using quantum computing and then quantifies the impact of active space choices across the VQE pipeline for quantum drug discovery. The suite covers several representative drug-like molecules (e.g., lovastatin, oseltamivir, morphine) and uses chemically motivated active spaces. Our VQE evaluations employ both simulation and quantum processing unit (QPU) execution using unitary coupled-cluster with singles and doubles (UCCSD) and hardware-efficient ansatz (HEA). We adopt a more comprehensive evaluation, including chemistry metrics and architecture-centric metrics. For accuracy, we compare them with classical quantum chemistry methods. This work establishes the first systematic benchmark for active space driven VQE and lays the groundwork for future hardware-algorithm co-design studies in quantum drug discovery.
The Variational Quantum Eigensolver (VQE) is a promising quantum algorithm for applications in chemistry within the Noisy Intermediate-Scale Quantum (NISQ) era. The ability for a quantum computer to simulate electronic structures with high accuracy would have a profound impact on material and biochemical science with potential applications e.g., to the development of new drugs. However, considering the variety of quantum hardware architectures, it is still uncertain which hardware concept is most suited to execute the VQE for e.g., the simulation of molecules. Aspects to consider here are the required connectivity of the quantum circuit used, the size and the depth and thus the susceptibility to noise effects. Besides theo-retical considerations, empirical studies using available quantum hardware may help to clarify the question of which hardware technology might be better suited for a certain given application and algorithm. Going one step into this direction, within this work, we present results using the VQE for the simulation of the hydrogen molecule, comparing superconducting and ion trap quantum computers. The experiments are carried out with a standardized setup of ansatz and optimizer, selected to reduce the number of required iterations. The findings are analyzed considering different quantum processor types, calibration data as well as the depth and gate counts of the circuits required for the different hardware concepts after transpilation.
Early-stage decisions in the pharmaceutical development process carry outsized consequences for eventual clinical success, yet the computational tools underpinning these decisions remain fundamentally constrained. Computer-aided drug design (CADD) has transformed how researchers navigate chemical space and predict ligand–target interactions, but classical implementations rely on mechanical force-field approximations that fail to capture polarisation, charge transfer, and electron correlation effects central to molecular recognition and reactivity. Quantum-mechanical treatments that correctly describe these phenomena scale exponentially with system size on classical hardware, rendering them impractical for drug-relevant biomolecules. Quantum computing offers a physically motivated path beyond this scaling barrier: by exploiting superposition, entanglement, and interference, quantum algorithms can in principle simulate electronic structure with polynomial resource requirements for targeted problem classes. This article provides a theoretical review of how quantum computation integrates throughout the drug discovery pipeline, from target identification to lead optimisation. Its primary contribution is a pipeline-level mapping of quantum methods—including the Variational Quantum Eigensolver (VQE), quantum machine learning, and quantum-enhanced optimisation—to specific drug development stages. The review critically distinguishes near-term NISQ (Noisy Intermediate-Scale Quantum: current devices with 50–1,000 noisy qubits operating without full error correction) capabilities from fault-tolerant quantum computing (FTQC) requirements, quantifies current resource gaps through a worked CYP3A4 case study, and identifies algorithmic limitations (barren plateaus, ansatz expressibility, measurement overhead), hardware scalability, and error correction overhead as the principal barriers to practical deployment.
Accurate determination of ground-state energies for molecules remains a challenge in quantum chemistry and a cornerstone for progress in fields such as drug discovery and materials design. The Variational Quantum Eigensolver (VQE) represents a leading hybrid quantum-classical paradigm for addressing this challenge; however, its widespread realization is limited by noise and the restricted scalability of current quantum hardware. Achieving efficient simulations on Noisy Intermediate-Scale Quantum (NISQ) devices and forthcoming Fault-Tolerant Application-Scalable Quantum (FASQ) systems demands a detailed understanding of how computational resources scale with molecular complexity and fermion-to-qubit encodings. In this study, resource requirements for VQE implementations employing the Unitary Coupled Cluster Singles and Doubles (UCCSD) ansatz are systematically analyzed. The molecular Hamiltonian is formulated in second quantization and mapped to qubit operators through the Jordan-Wigner (JW), Bravyi-Kitaev (BK), and Parity (Pa) transformations. Hamiltonian reduction strategies, including Z2 tapering and frozen-core approximations, are examined to assess their effect on quantum resource scaling. The analysis reveals that appropriate transformations, when combined with symmetry-based reductions, can substantially reduce qubit counts by up to ≈50% and quantum gate counts by up to ≈27.5× and Hamiltonian Pauli string counts by up to ≈2.75×, relative to the corresponding unreduced Hamiltonian representations within the same active-space configuration for the representative set of molecular systems under study. These findings provide practical circuit-level insights for executing chemically relevant simulations on NISQ hardware, while establishing physical-resource baselines that may inform future logical-level analyses targeting FASQ systems.
Abstract We present a quantum chemistry benchmark for noisy intermediate-scale quantum computers that leverages the variational quantum eigensolver, active-space reduction, a reduced unitary coupled cluster ansatz, and reduced density purification as error mitigation. We demonstrate this benchmark using 4 of the available qubits on the 20-qubit IBM Tokyo and 16-qubit Rigetti Aspen processors via the simulation of alkali metal hydrides (NaH, KH, RbH), with accuracy of the computed ground state energy serving as the primary benchmark metric. We further parameterize this benchmark suite on the trial circuit type, the level of symmetry reduction, and error mitigation strategies. Our results demonstrate the characteristically high noise level present in near-term superconducting hardware, but provide a relevant baseline for future improvement of the underlying hardware, and a means for comparison across near-term hardware types. We also demonstrate how to reduce the noise in post processing with specific error mitigation techniques. Particularly, the adaptation of McWeeny purification of noisy density matrices dramatically improves accuracy of quantum computations, which, along with adjustable active space, significantly extends the range of accessible molecular systems. We demonstrate that for specific benchmark settings and a selected range of problems, the accuracy metric can reach chemical accuracy when computing over the cloud on certain quantum computers.
In recent years, the Variational Quantum Eigensolver (VQE) has emerged as one of the most popular algorithms for solving the electronic structure problem on near-term quantum computers. The utility of VQE is often hindered by the limitations of current quantum hardware, including, but not limited to, short qubit coherence times and low gate fidelities. These limitations become particularly pronounced when VQE is used along with deep quantum circuits, such as those required by the ”Unitary Coupled Cluster Singles and Doubles” (UCCSD) ansatz, often resulting in significant errors. To address these issues, we propose a low-depth ansatz based on parallelized Givens rotations, which can recover substantial correlation energy while drastically reducing circuit depth and two-qubit gate counts for an arbitrary active space (AS). Also, considering the current hardware architectures with low qubit counts, we introduce a systematic way to select molecular orbitals to define active spaces (ASs) that retain significant electron correlation. We validate our approach by computing bond dissociation profiles of water and strongly correlated systems, such as molecular nitrogen and oxygen, across various ASs. Noiseless simulations using the new ansatz yield ground-state energies comparable to those from the UCCSD ansatz while reducing circuit depth by 50–70%. Moreover, in noisy simulations, our approach achieves energy error rates an order of magnitude lower than that of UCCSD. Considering the efficiency and practical usage of our ansatz, we hope that it becomes a potential choice for performing quantum chemistry calculations on near-term quantum devices.
Quantum chemistry plays a crucial role in advancing fundamental understanding of chemical processes and driving innovation in energy, medicine, and materials science. Recent progress in quantum computing has opened new possibilities for molecular simulations that are beyond the practical limits of classical approaches. Academic studies have demonstrated hybrid Density Functional Theory (DFT) and Variational Quantum Eigensolver (VQE) benchmarks on small transition-metal systems, such as iron porphyrin and heme analogues, using current noisy intermediate-scale quantum (NISQ) hardware. Although full-scale simulations of complex biological systems such as the complete Cytochrome P450 (CYP450) active site remain a long-term goal due to limitations in qubit numbers, coherence times, and error correction, the underlying methodologies are now well established. At present, quantum chemistry applications in drug discovery remain largely experimental, and widespread practical medical impact is expected to require further technological advances over the next 5–10 years. Nevertheless, quantum software and algorithm development for chemical applications is progressing rapidly. This perspective summarizes recent advances in quantum computing algorithms, hardware, and software relevant to chemistry, and critically discusses the remaining challenges and opportunities for applying quantum computing to chemical problems, with particular emphasis on drug discovery and development.